Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

出版年份 2019 全文链接

标题

作者

关键词

出版物

Volume 37, Issue 15_suppl, Pages 4012-4012

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2019-05-28

DOI

10.1200/jco.2019.37.15_suppl.4012

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started